AMP-activated protein kinase (AMPK) negatively regulates mammalian target of rapamycin (mTOR), the master regulator of translational machinery and cell growth. Recently, we demonstrated that the progressive left ventricular (LV) hypertrophy and heart failure (HF) caused by transverse aortic constriction (TAC) is exacerbated in mice with AMPK12 gene deficiency (AMPK12-/-), and this was associated with increased p- p70S6KThr389, a downstream target of mTOR complex 1 (mTORC1). We also found that activation of AMPK with AICAR or metformin, or overexpression of constitutively active AMPK12, all significantly attenuated cardiac myocyte hypertrophy and p-p70S6KThr389 in vitro. However, the mechanism by which loss of AMPK12 causes increased activation of the mTORC1/p-p70S6k Thr389 signaling pathway after TAC is not clear. DNA-damage-inducible transcript 4 (DDIT4) is a novel stress-responsive gene that negatively regulates the mTORC1 pathway in several tumor-derived cell lines. Although no published studies examining DDIT4 in the heart are available, using global microarray profiling we found that AMPK12-/- mice have decreased expression of myocardial DDIT4. These findings suggest that DDIT4 could provide the essential link by which AMPK12-/- causes activation of the mTORC1 and thereby exacerbates LV hypertrophy during stress conditions. Consequently, studies are proposed to determine whether the novel mTORC1 suppressor DDIT4 is instrumental in attenuating TAC-induced LV hypertrophy and HF in mice after TAC, and the molecular mechanisms by which AMPK12 facilitates adaptation of the heart to hemodynamic overload. Our central hypothesis is that DDIT4 attenuates chronic TAC-induced cardiac myocyte hypertrophy by attenuating the mTORC1 signaling pathway. We also hypothesize that AMPK regulates mTORC1 signaling at least partially through DDIT4. We plan to test our central hypothesis by pursuing the following two Specific Aims: i) Identify the overall impact of DDIT4 on myocardial mTORC1 signaling, LV hypertrophy and HF. Our working hypothesis is that DDIT4 gene deficiency (DDIT4-/-) will amplify activation of the mTOR signaling pathway and LV hypertrophy that occurs when hearts are exposed to systolic overload;ii) Determine the molecular mechanism by which AMPK attenuates mTORC1/p70s6k activation and cardiac myocyte hypertrophy. Our working hypothesis is that DDIT4 plays an essential role for AMPK to attenuate pathological LV hypertrophy. The project is innovative as no previous studies have examined the influence of DDIT4 on LV hypertrophy and HF. Using DDIT4-/- mice combined with TAC will allow us to decipher the role of DDIT4 in attenuating cardiac myocyte hypertrophy under clinically relevant conditions. This project is significant as the knowledge obtained will lead to a better understanding of the molecular mechanisms mediating ventricular hypertrophy and HF, which may provide the basis for developing specific interventions to treat these diseases.

Public Health Relevance

DNA-damage-inducible transcript 4 (DDIT4) is a novel stress-responsive gene that negatively regulate the mTOR pathway in tumor cell lines. However, the effect of DDIT4 on ventricular hypertrophy and dysfunction has not been studied. Using global microarray profiling we recently found that AMPK12 KO mice have decreased expression of myocardial DDIT4, a change may explain the enhanced activation of myocardial mTOR signaling and ventricular hypertrophy in AMPK12 mice in response to chronic stress overload. Studies are proposed to determine whether the novel mTOR suppressor DDIT4 is instrumental in attenuating the development of ventricular hypertrophy and heart failure.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Exploratory/Developmental Grants (R21)
Project #
Application #
Study Section
Cardiac Contractility, Hypertrophy, and Failure Study Section (CCHF)
Program Officer
Adhikari, Bishow B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Minnesota Twin Cities
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Bache, Robert J; Chen, Yingjie (2014) NOX2-induced myocardial fibrosis and diastolic dysfunction: role of the endothelium. J Am Coll Cardiol 63:2742-4
Liu, Xiaoyu; Kwak, Dongmin; Lu, Zhongbing et al. (2014) Endoplasmic reticulum stress sensor protein kinase R-like endoplasmic reticulum kinase (PERK) protects against pressure overload-induced heart failure and lung remodeling. Hypertension 64:738-44
Wang, Huan; Xu, Xin; Fassett, John et al. (2014) Double-stranded RNA-dependent protein kinase deficiency protects the heart from systolic overload-induced congestive heart failure. Circulation 129:1397-406
Xu, Xin; Lu, Zhongbing; Fassett, John et al. (2014) Metformin protects against systolic overload-induced heart failure independent of AMP-activated protein kinase ?2. Hypertension 63:723-8
Lu, Zhongbing; Xu, Xin; Fassett, John et al. (2014) Loss of the eukaryotic initiation factor 2* kinase general control nonderepressible 2 protects mice from pressure overload-induced congestive heart failure without affecting ventricular hypertrophy. Hypertension 63:128-35
Chen, Yingjie; Guo, Haipeng; Xu, Dachun et al. (2012) Left ventricular failure produces profound lung remodeling and pulmonary hypertension in mice: heart failure causes severe lung disease. Hypertension 59:1170-8
Xu, Dachun; Guo, Haipeng; Xu, Xin et al. (2011) Exacerbated pulmonary arterial hypertension and right ventricular hypertrophy in animals with loss of function of extracellular superoxide dismutase. Hypertension 58:303-9
Fassett, John T; Hu, Xinli; Xu, Xin et al. (2011) Adenosine kinase regulation of cardiomyocyte hypertrophy. Am J Physiol Heart Circ Physiol 300:H1722-32
Zhang, Ping; Hu, Xinli; Xu, Xin et al. (2011) Dimethylarginine dimethylaminohydrolase 1 modulates endothelial cell growth through nitric oxide and Akt. Arterioscler Thromb Vasc Biol 31:890-7
Hu, Xinli; Atzler, Dorothee; Xu, Xin et al. (2011) Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine. Arterioscler Thromb Vasc Biol 31:1540-6

Showing the most recent 10 out of 11 publications